vs
Side-by-side financial comparison of BJs RESTAURANTS INC (BJRI) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
BJs RESTAURANTS INC is the larger business by last-quarter revenue ($355.4M vs $196.9M, roughly 1.8× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -73.8%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 2.6%).
BJ's Restaurants Inc. operates a chain of casual dining restaurants across the United States. Its menu features signature deep-dish pizzas, craft beers, handcrafted cocktails, and a wide range of American comfort food. The brand primarily serves family groups, friend gatherings, and casual diners seeking affordable, high-quality meals in a relaxed, welcoming in-store environment.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BJRI vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $355.4M | $196.9M |
| Net Profit | $12.6M | — |
| Gross Margin | 74.5% | 79.5% |
| Operating Margin | — | 1.2% |
| Net Margin | 3.6% | — |
| Revenue YoY | -73.8% | 5.1% |
| Net Profit YoY | -24.2% | — |
| EPS (diluted) | $0.58 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $355.4M | $196.9M | ||
| Q3 25 | $365.6M | $179.5M | ||
| Q2 25 | $348.0M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | $325.7M | $187.3M | ||
| Q3 24 | $349.9M | $168.6M | ||
| Q2 24 | $337.3M | $178.0M | ||
| Q1 24 | — | $167.1M |
| Q4 25 | $12.6M | — | ||
| Q3 25 | $22.2M | $5.4M | ||
| Q2 25 | $13.5M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | $-2.9M | — | ||
| Q3 24 | $17.2M | $-143.5M | ||
| Q2 24 | $7.7M | $18.9M | ||
| Q1 24 | — | $9.0M |
| Q4 25 | 74.5% | 79.5% | ||
| Q3 25 | 75.2% | 80.9% | ||
| Q2 25 | 75.0% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | 73.4% | 78.7% | ||
| Q3 24 | 74.3% | 76.9% | ||
| Q2 24 | 74.8% | 75.1% | ||
| Q1 24 | — | 71.6% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | 5.8% | 3.5% | ||
| Q2 25 | 4.3% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | -0.8% | 13.2% | ||
| Q3 24 | 3.8% | -82.8% | ||
| Q2 24 | 2.4% | 15.9% | ||
| Q1 24 | — | 7.9% |
| Q4 25 | 3.6% | — | ||
| Q3 25 | 6.1% | 3.0% | ||
| Q2 25 | 3.9% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | -0.9% | — | ||
| Q3 24 | 4.9% | -85.1% | ||
| Q2 24 | 2.3% | 10.6% | ||
| Q1 24 | — | 5.4% |
| Q4 25 | $0.58 | $0.05 | ||
| Q3 25 | $0.97 | $0.12 | ||
| Q2 25 | $0.58 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | $-0.13 | $0.38 | ||
| Q3 24 | $0.72 | $-3.11 | ||
| Q2 24 | $0.32 | $0.39 | ||
| Q1 24 | — | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.8M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $366.2M | $693.1M |
| Total Assets | $1.0B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.8M | $238.4M | ||
| Q3 25 | $26.0M | $246.3M | ||
| Q2 25 | $19.0M | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $18.4M | $484.6M | ||
| Q3 24 | $16.2M | $453.8M | ||
| Q2 24 | $18.8M | $404.2M | ||
| Q1 24 | — | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | $60.5M | $376.7M | ||
| Q2 25 | $85.5M | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $66.5M | $585.3M | ||
| Q3 24 | $63.5M | — | ||
| Q2 24 | $58.0M | — | ||
| Q1 24 | — | — |
| Q4 25 | $366.2M | $693.1M | ||
| Q3 25 | $386.6M | $727.2M | ||
| Q2 25 | $371.5M | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | $376.2M | $778.3M | ||
| Q3 24 | $386.5M | $749.6M | ||
| Q2 24 | $375.4M | $879.3M | ||
| Q1 24 | — | $892.2M |
| Q4 25 | $1.0B | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $1.0B | $1.6B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | — | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | 0.16× | 0.52× | ||
| Q2 25 | 0.23× | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.18× | 0.75× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $43.7M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 22.1% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $43.7M | ||
| Q3 25 | $62.3M | $60.8M | ||
| Q2 25 | $4.6M | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | $27.3M | $33.1M | ||
| Q3 24 | $20.2M | $53.9M | ||
| Q2 24 | $22.3M | $53.2M | ||
| Q1 24 | — | $49.1M |
| Q4 25 | — | $43.5M | ||
| Q3 25 | $41.9M | $57.0M | ||
| Q2 25 | $-12.1M | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $7.6M | $31.0M | ||
| Q3 24 | $735.0K | $49.8M | ||
| Q2 24 | $448.0K | $51.6M | ||
| Q1 24 | — | $46.3M |
| Q4 25 | — | 22.1% | ||
| Q3 25 | 11.5% | 31.7% | ||
| Q2 25 | -3.5% | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | 2.3% | 16.6% | ||
| Q3 24 | 0.2% | 29.6% | ||
| Q2 24 | 0.1% | 29.0% | ||
| Q1 24 | — | 27.7% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 5.6% | 2.2% | ||
| Q2 25 | 4.8% | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 6.0% | 1.1% | ||
| Q3 24 | 5.6% | 2.4% | ||
| Q2 24 | 6.5% | 0.9% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | 2.80× | 11.20× | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 2.89× | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BJRI
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
